Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States, shoring up domestic manufacturing as President Donald Trump threatens new tariffs on pharmaceuticals.

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.